Publications by authors named "Carlos Ariel Pulido-Vicuna"
Genes limiting T cell antitumor activity may serve as therapeutic targets. It has not been systematically studied whether there are regulators that uniquely or broadly contribute to T cell fitness. We perform genome-scale CRISPR-Cas9 knockout screens in primary CD8 T cells to uncover genes negatively impacting fitness upon three modes of stimulation: (1) intense, triggering activation-induced cell death (AICD); (2) acute, triggering expansion; (3) chronic, causing dysfunction.
View Article and Find Full Text PDFArticle Synopsis
- Researchers studied the cellular structure of melanoma tumors and their changes when treated with immune checkpoint blockade (ICB) to understand why some patients resist this therapy.
- They found that a specific cell type with a mesenchymal-like (MES) state, which is associated with resistance to treatment, was more common in patients who did not respond to ICB.
- The study identified TCF4 as a key regulator that controls this resistance by suppressing other important immune functions, and targeting TCF4 could enhance the effectiveness of both ICB and other therapies in melanoma treatment.